玮俊生物科技(00660.HK)拟根据特定授权发行6700万港元可换股债
格隆汇 7 月 28日丨玮俊生物科技(00660.HK)发布公告,2020年7月28日,公司与认购人黄志勇先生订立该认购协议,据此,公司有条件同意发行本金总额为6700万港元的可换股债券。
可换股债券附带换股权,可按换股价每股换股股份0.022港元(可予调整)转换为换股股份,以作为债务清偿。该认购人根据该认购协议应付的认购款项将透过抵销公司应付予该认购人及╱或其联系人的该贷款(预期于完成日期将合共为6700万港元)项下的未偿还本金额及应计利息而偿付。
假设换股权按换股价悉数行使,则在若干换股限制的规限下可根据该认购协议而向该认购人配发及发行合共约30.45亿股新股份(即换股股份)。换股股份相当于该公告日期全部已发行股份数目约18.36%以及经向该名认购人配发及发行换股股份扩大的全部已发行股份数目约15.51%,当中假设于该公告日期至换股权获悉数行使的日期的股份总数并无其他变动。换股股份将根据将于股东特别大会上征求股东批准的特定授权而配发及发行。
公司不会申请让可换股债券于联交所上市。公司将向联交所上市委员会申请批准换股股份上市及买卖。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.